We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial.
- Authors
Lebellec, Loïc; Bertucci, François; Tresch-Bruneel, Emmanuelle; Ray-Coquard, Isabelle; Le Cesne, Axel; Bompas, Emmanuelle; Blay, Jean-Yves; Italiano, Antoine; Mir, Olivier; Ryckewaert, Thomas; Toiron, Yves; Camoin, Luc; Goncalves, Anthony; Penel, Nicolas; Le Deley, Marie-Cécile
- Abstract
<bold>Background: </bold>We report here a correlation analysis conducted along with a phase II trial assessing bevacizumab in combination with weekly paclitaxel.<bold>Methods: </bold>Circulating pro/anti-angiogenic factors were assessed on day 1 (D1) and day 8 (D8). The prognostic value for progression-free survival (PFS) was evaluated using a Cox model with biomarkers as continuous variables.<bold>Results: </bold>Among the 51 patients enrolled and treated in this trial, biomarker analysis was performed for 42: 18 in Arm A (single-agent) and 24 in Arm B (combination). With a median follow-up of 46 months, PFS was 5.5 versus 5.7 months, respectively (p = 0.75). According to univariate analysis, factors associated with a poor PFS were as follows: visceral angiosarcoma, de novo angiosarcoma, and high PlGF and low VEGF-C baseline values. In multivariate analysis, de novo angiosarcoma (HR = 2.5; p = 0.024) and baseline VEGF-C value (HR = 0.7; p = 0.003) were significant prognostic factors. We observed a significant increase in circulating PlGF (< 0.001) and a decrease in VEGF (< 0.001) during bevacizumab treatment. An increase in FGF was associated with a poor outcome.<bold>Conclusions: </bold>De novo angiosarcoma and a low baseline level of VEGF-C were found to be associated with a poor prognosis. Addition of bevacizumab induces major changes in circulating biomarkers (VEGF and PlGF) in a short timeframe without impacting PFS.<bold>Trial Registration: </bold>Retrospectively registered on EudraCT N° 2009-017020-59 and NCT01303497 (February 24, 2011).
- Subjects
ANGIOSARCOMA; BEVACIZUMAB; PACLITAXEL; VASCULAR endothelial growth factors; CLINICAL trials; PROGRESSION-free survival; THERAPEUTICS; ANTINEOPLASTIC agents; COMPARATIVE studies; RESEARCH methodology; MEDICAL cooperation; PROGNOSIS; RESEARCH; RESEARCH funding; SARCOMA; EVALUATION research; RANDOMIZED controlled trials
- Publication
BMC Cancer, 2018, Vol 18, Issue 1, p1
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/s12885-018-4828-1